Novel 2-(2'-furo[3,2-b]pyridinyl) pyrrolidines: Potent neuronal nicotinic acetylcholine receptor ligands

Bioorganic and Medicinal Chemistry Letters

Volumn 7, Issue 21, 1997, Pages 2703-2708

  Elliott, Richard L ^a,b   Ryther, Keith B ^a   Anderson, David J ^a   Piattoni Kaplan, Marietta ^a   Kuntzweiler, Theresa A ^a   Donnelly Roberts, Diana ^a   Arneric, Stephen P ^a   Holladay, Mark W ^a  

^a ABBOTT LABORATORIES   (United States)

^b Dept 47N ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2' FURO[3,2 B]PYRIDINYL) PYRROLIDINE DERIVATIVE; 3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; A 84543; LIGAND; NICOTINE; NICOTINIC RECEPTOR; PARTIAL AGONIST; PYRROLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; RAT; RECEPTOR AFFINITY; STEREOCHEMISTRY;

EID: 0030780327     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(97)10080-4     Document Type: Article

References (23)

1. (a) Arneric, S. P.; Holladay, M. W.; Sullivan, J. P. Exp. Opin. Invest. Drugs, 1996; 5, 79;
2. (b) Holladay, M. W.; Lebold. S. A.; Lin, N-H. Drug Dev. Res. 1995, 35, 191;
3. Williams, M.: Sullivan, J. P.; Arneric, S. P. Drug.News Perspect. 1994, 7, 205.
4. (a) Garvey, D. S.; Wasicak, J. T.; Decker, M. W.; Brioni, J. D.; Buckley, M. J.; Sullivan, J. P.; Carrera, G. M.; Holladay, M. W.; Arneric, S. P.; Williams, M. J. Med. Chem. 1994, 37, 1055.
5. (b) Arneric, S. P. Sullivan, J. P.; Briggs, C. A; Donnelly-Roberts, D. L.; Anderson, D. J.; Raszkiewicz, J. L.; Hughes, M. Cadman, E. D.; Adams, P.; Garvey, D. S.; Wasicak, J.; Williams, M. J. Pharmacol. Exp. Therap. 1994, 270, 310;
6. Decker, M. W.; Brioni, J. D.; Sullivan, J. P.; Buckley, M. J.; Radek, R. J.; Raszkiewicz, J. L.; Kang C. H.; Kim, D. J. B.; Giardina, W. J.; Wasicak, J.; Garvey, D. S.; Williams, M.; Arneric, S. P. J. Pharm. Exp. Ther. 1994, 270, 319;
7. Garvey, D. S.; Wasicak, J. T.; Elliott, R. L.; Lebold, S. A.; Hettinger, A-M. Carrera, G. M.; Lin, N-H.; He, Y.; Holladay, M. W.; Anderson, D. J.; Cadman, E. D.; Raszkiewicz, J. L.; Sullivan, J. P.; and Arneric, S. P. J. Med. Chem. 1994, 37, 4455;
8. (e) Arneric, S. P.; Anderson, D. J.; Bannon, A. W.; Briggs, C. A.; Buccafusco, J. J.; Brioni, J. D.; Cannon, J. B.; Decker, M. W.; Donnelly-Roberts, D. L.; Gopalakrishnan, M.; Holladay, M. W.; Kyncl, J.; Marsh, K. C.; Pauly, J.; Radek, R. J.; Rodrigues, A. D.; Sullivan, S. P. CNS Drug Reviews 1995, I, 1.
9. (a) Abreo, M. A.; Lin, N-H.; Garvey, D. S.; Gunn, D. E.; Hettinger, A-M.; Wasicak, J. T.; Pavlik, P. A.; Martin,Y. C.; Donnelly-Roberts, D. L.; Anderson, D. J.; Sullivan, J. P.; Williams, M.; Arneric, S. P.; Holladay, M. W. J. Med. Chem. 1996, 39, 817;
10. (b) Lin, N-H; Gunn, D. E.; Ryther, K. B.; Garvey, D. S.; Donnelly-Roberts, D. L.; Decker, M. W.; Brioni, J. D.; Buckley, M. J.; Rodrigues, D.; Marsh, K. G.; Anderson, D. J.; Buccafusco, J. J.; Prendergast, M. A.; Sullivan, J. P.; Williams, M.; Arneric, S. P.; Holladay, M. W. J. Med. Chem. 1997, 40, 385.
11. Kundu, N. G.; Pal, M.; Mahanty, J. S.; Dasgupta, S. K. JCS Chem. Commun., 1992, 1, 41.
12. 3/EtOH.
13. Pabreza, L. A.; Dhawan, S.; Kellar, K. J. Mol. Pharmacol. 1990, 39, 9.
14. Gopalakrishnan, M., Monteggia, L. M., Anderson, D. J., Arneric, S. P. and Sullivan, J. P. J. Pharamacol. Exp. Ther., 1996, 276, 289.
15. Sullivan, J. P.; Donnelly-Roberts, D. L.; Briggs, C. A.; Gopalakrishnan, M.; Hu, I.; Campbell, J. E.; Anderson, D. J.; Piattoni-Kaplan, M.; Molinari, E.; McKenna, D. G.; Gunn, D. E.; Lin, N-H.; Ryther, K. B.; He, Y.; Holladay, M. W.; Williams, M.; Arneric, S. P. J. Pharmacol. Exp. Ther. 1997, (in press)
16. i values for the 2(S)-NH; 2(R)-NH; 2(S)-NMe and 2(R)-NMe isomers of nicotine, furopyridine pyrrolidines, isoxazole pyrrolidines, and the pyridyl ether class are as follows: nicotine isomers: 22.0 ± 3.0, 17.0 ± 2.0, 1.1 ± 0.4, 16.0 ± 3.4; furopyridine pyrrolidines: 75.8 ± 2.6, 5.11 ± 1.0, 2.73 ± 0.45, 97.87 ± 8.85; isoxazole pyrrolidines: 333 ± 50, 7.4 ± 0.7, 4.2 ± 0.6, 44 ± 12; pyridyl ethers: 0.16 ± 0.06, 0.14 ± 0.03, 0.15 ± 0.01, 19.7 ± 4.4, respectively, as reported in references 2 and 3.
17. Lukas, R. J.; Cullen, M. J. Anal. Biochem. 1988, 175, 212.
18. Flores, C. M.; Rogers, S. W.; Pabreza, L. A.; Wolfe, B. B.; Kellar, K. J. Mol. Pharmacol. 1992, 41, 31.
19. (a) Grady, S.; Marks, M. J.; Wonnacott, S. Collins, A. C. J. Neurochem. 1992, 59, 848;
20. (b) Rapier, C,. Lunt, G. G.; Wonnacott, S; J. Neurochem. 1990, 50, 1123.
21. (a) Clarke, P. B. S.; Pert, A. Brain Res. 1985, 348, 355;
22. (b) Rapier, C,. Lunt, G. G.; Wonnacott, S. J. Neurochem. 1990, 50, 1123.
23. Luther, M. A.; Schoepfer, R.; Whiting, P.; Casey, B.; Blatt, Y.; Montal, M. S.; Montal, M.; Lindstrom, J. J. Neurosci. 1989, 9, 1082.